October 5, 2016 – AbbVie has announced that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for VENCLEXTA™ (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukemia (CLL) patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of VENCLEXTA.
“Based on the efficacy and safety profile observed in clinical trials, VENCLEXTA is proving to be a highly valuable therapy for relapsed/refractory CLL patients, who have few, and in some cases, no treatment options available to them,” said Dr. April Shamy, hematologist at Montreal’s Jewish General Hospital, a McGill University teaching hospital, and participating physician in the VENCLEXTA clinical trial program. “Furthermore, because VENCLEXTA is an oral medication, it is much more convenient for patients than intravenous therapies, which are often disruptive to patients’ lives.”